Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Identification of human butyrylcholinesterase organophosphate-resistant variants through a novel mammalian enzyme functional screen.

Zhang J, Chen S, Ralph EC, Dwyer M, Cashman JR.

J Pharmacol Exp Ther. 2012 Dec;343(3):673-82. doi: 10.1124/jpet.112.198499. Epub 2012 Sep 6.

2.

Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior.

Masson P, Lockridge O.

Arch Biochem Biophys. 2010 Feb 15;494(2):107-20. doi: 10.1016/j.abb.2009.12.005. Epub 2009 Dec 11. Review.

3.

Progress in the development of enzyme-based nerve agent bioscavengers.

Nachon F, Brazzolotto X, Trovaslet M, Masson P.

Chem Biol Interact. 2013 Dec 5;206(3):536-44. doi: 10.1016/j.cbi.2013.06.012. Epub 2013 Jun 26. Review.

PMID:
23811386
4.

Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review.

Lenz DE, Yeung D, Smith JR, Sweeney RE, Lumley LA, Cerasoli DM.

Toxicology. 2007 Apr 20;233(1-3):31-9. Epub 2006 Dec 1. Review.

PMID:
17188793
5.

Mechanisms of organophosphate toxicity and detoxication with emphasis on studies in Croatia.

Reiner E, Radić Z, Simeon-Rudolf V.

Arh Hig Rada Toksikol. 2007 Sep;58(3):329-38. Review.

PMID:
17913688
6.

Identification and characterization of biomarkers of organophosphorus exposures in humans.

Kim JH, Stevens RC, MacCoss MJ, Goodlett DR, Scherl A, Richter RJ, Suzuki SM, Furlong CE.

Adv Exp Med Biol. 2010;660:61-71. doi: 10.1007/978-1-60761-350-3_7. Review.

7.

Complex view on poisoning with nerve agents and organophosphates.

Bajgar J.

Acta Medica (Hradec Kralove). 2005;48(1):3-21. Review.

8.

Detoxification of organophosphate nerve agents by bacterial phosphotriesterase.

Ghanem E, Raushel FM.

Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):459-70. Review.

PMID:
15982683
9.

A comparison of organophosphate degradation genes and bioremediation applications.

Iyer R, Iken B, Damania A.

Environ Microbiol Rep. 2013 Dec;5(6):787-98. doi: 10.1111/1758-2229.12095. Epub 2013 Sep 16. Review.

PMID:
24249287
10.

Rational design of an enzyme mutant for anti-cocaine therapeutics.

Zheng F, Zhan CG.

J Comput Aided Mol Des. 2008 Sep;22(9):661-71. Epub 2007 Nov 8. Review.

11.

Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses.

Lockridge O.

Pharmacol Ther. 2015 Apr;148:34-46. doi: 10.1016/j.pharmthera.2014.11.011. Epub 2014 Nov 20. Review.

PMID:
25448037
12.

Review of tyrosine and lysine as new motifs for organophosphate binding to proteins that have no active site serine.

Lockridge O, Schopfer LM.

Chem Biol Interact. 2010 Sep 6;187(1-3):344-8. doi: 10.1016/j.cbi.2010.03.002. Epub 2010 Mar 6. Review.

Items per page

Supplemental Content

Write to the Help Desk